

# Management of stable acute respiratory infections during winter surges in NSW

June 2022

The Agency for Clinical Innovation (ACI) is the lead agency for innovation in clinical care.

We bring consumers, clinicians and healthcare managers together to support the design, assessment and implementation of clinical innovations across the NSW public health system to change the way that care is delivered.

The ACI's clinical networks, institutes and taskforces are chaired by senior clinicians and consumers who have a keen interest and track record in innovative clinical care.

We also work closely with the Ministry of Health and the four other pillars of NSW Health to pilot, scale and spread solutions to healthcare system-wide challenges. We seek to improve the care and outcomes for patients by re-designing and transforming the NSW public health system.

Our innovations are:

- person-centred
- clinically-led
- evidence-based
- value-driven.

**[www.aci.health.nsw.gov.au](http://www.aci.health.nsw.gov.au)**

## **AGENCY FOR CLINICAL INNOVATION**

1 Reserve Road St Leonards NSW 2065

Locked Bag 2030, St Leonards NSW 1590

T +61 2 9464 4666

E [aci-info@nsw.gov.au](mailto:aci-info@nsw.gov.au) | [aci.health.nsw.gov.au](http://aci.health.nsw.gov.au)

SHPN (ACI) 220481; ISBN 978-1-76023-238-2

**Disclaimer:** Content within this publication was accurate at the time of publication. This work is copyright. It may be reproduced in whole or part for study or training purposes subject to the inclusion of an acknowledgment of the source. It may not be reproduced for commercial usage or sale. Reproduction for purposes other than those indicated above, requires written permission from the NSW Agency for Clinical Innovation.

**Version:** 1 **Trim:** ACI/D22/1168

**Date published:** June 2022

© **Agency for Clinical Innovation 2022**

## Contents

<b>Introduction .....</b>	<b>3</b>
Purpose and scope.....	3
Methodology .....	3
<b>Acute respiratory infection (ARI).....</b>	<b>4</b>
Causes.....	4
Symptoms.....	4
Isolation requirements .....	4
Susceptibility to complications .....	4
Testing .....	5
Infection prevention and control.....	5
<b>Patient cohort and management strategies .....</b>	<b>6</b>
Table 1. Severity definitions of ARI in adults (>16 years), with suggested management approach .....	6
Table 2. Severity definitions of ARI in children (<16 years), with suggested management approach .....	8
Acute treatment for ARI .....	9
Influenza .....	9
COVID-19.....	9
<b>Principles of operationalising models of care .....</b>	<b>10</b>
Site selection and layout.....	10
Access and referral.....	10
Setting and delivery modes .....	10
Staffing.....	10
Policy and procedures .....	11
Equipment.....	11
Stakeholders and partnerships .....	12
Figure 1. Decision pathway: suitability for management in ARI diversion clinic .....	13
<b>Appendix 1. Pharmacological treatment for influenza .....</b>	<b>14</b>
Table 1. Medications for influenza treatment in adults and children.....	14
Table 2. Medications for influenza prophylaxis in adults and children.....	14

## Introduction

### Purpose and scope

This document is intended to support the management of people with stable differentiated and undifferentiated acute respiratory infections during winter surge periods.

It has been developed to assist health services to advise patients; assess the risk of serious complications; and to provide clinical guidance on the early acute management of these conditions with antiviral therapies, where appropriate.

This guide provides high-level advice and support to local health districts (LHDs) and specialty health networks (SHNs) to step-up and operationalise an acute respiratory infection (ARI) diversion clinic, when the need arises due to winter surge activity. This model is distinct from the pandemic response flu clinics.

This is a living document. It will continue to evolve and be updated through an iterative process of multispecialty consultations.

### Potential triggers for establishing a rapid ARI clinic

System-wide surge pressures across NSW Health will be the trigger for LHDs to step-up an ARI diversion clinic. This will differ for each LHD/SHN, with varying capacity limitations and pressures specific to the local context. ARI monitoring should be established through the local Public Health Unit.

Most of these patients should continue to be managed in primary care. The ARI clinics should be considered as an addition to the local health district's short term escalation plans (STEP) plans and associated strategies.

Examples of scenarios that may trigger an LHD/SHN to establish an ARI diversion clinic may include:

- where modelling projections or epidemiological data suggest an increase in ARI presentations that are likely to result in system pressures (including pressures on patient flow and bed allocation)
- significant community prevalence in the local population that impacts the emergency department (ED) through increased presentations.

### Methodology

The available evidence and evidence check undertaken by the [NSW Critical Intelligence Unit \(CIU\)](#) was considered by an expert group of NSW clinicians to inform the development of this guidance.<sup>1-3</sup> Emerging evidence is also being monitored by the CIU and will be included in this document, as required.

The evidence in regard COVID-19 and its early treatment is based on the recommendations of the National COVID-19 Clinical Evidence Taskforce (NCCET), which specifies recommendations for the use of anti-SARS-CoV-2 monoclonal antibodies and antivirals in adults and adolescents in Australia. The evidence regarding the early treatment of influenza is based on systematic reviews of the literature.<sup>4-7</sup>

Historical documents produced by NSW Health in relation to infectious disease clinics were reviewed to inform the operational considerations outlined in this document.<sup>8,9</sup>

This document should be read in conjunction with [medication safety guidance](#) and [infection prevention and control guidance](#) developed by the Clinical Excellence Commission (CEC).

## Acute respiratory infection (ARI)

### Causes

An acute respiratory infection (ARI) may be caused by several viruses, including:

- SARS-CoV-2 (responsible for COVID-19)
- Influenza A and B
- Respiratory syncytial virus (RSV)
- Parainfluenza
- Metapneumovirus
- Rhinoviruses
- Seasonal coronaviruses
- Adenovirus

### Symptoms

Symptoms of ARI are similar for influenza, COVID-19 and RSV. These include, new onset fever, sore throat, nasal congestion, runny nose, cough, fatigue or malaise, along with body aches. More serious infection can lead to breathlessness on exertion or, in severe cases, at rest.

Most people with an ARI will only experience a brief self-limiting illness. They will be able to manage with rest, analgesia and fluids at home.

ARIs can lead to lower respiratory complications, such as pneumonia and, in young children, bronchiolitis. ARIs often trigger acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD) and may worsen existing cardiac failure. These conditions will also require treatment.

Rarely, both influenza and COVID-19 may lead to a severe inflammatory syndrome, known as multisystem inflammatory syndrome. This is characterised by a severe illness with systemic inflammation and shock. This phenomenon may occur in adults and children.<sup>10, 11</sup>

### Isolation requirements

People with ARI symptoms should generally not return to work or school until their acute symptoms have resolved (noting that some symptoms, such as post viral cough, may persist for weeks). The infection can be transmitted to other people, so those working with susceptible populations should not return to work until asymptomatic and the recommended timeframe is reached for the specific respiratory infection (pathogen); where not identified this should be for seven days.

People with COVID-19 must follow the current NSW Public Health orders and guidance on isolation following confirmation of a positive test result.<sup>12</sup>

People (including health workers) with influenza are considered no longer infectious if 24 hours have elapsed since the resolution of fever, provided either:

- they have received 72 hours of anti-influenza medication; or
- five days have elapsed since onset of respiratory symptoms.

Children and younger adults may shed influenza virus for 10 or more days, and immunosuppressed persons may shed all viruses for weeks. However, the ability to transmit infection is likely to be higher when respiratory symptoms are present.<sup>13</sup>

### Susceptibility to complications

Certain groups are more susceptible to complications from ARIs, and should be considered for closer monitoring and early use of antiviral therapies against influenza and/or COVID-19.

In adults (>16 years), the following groups may be susceptible:

- Age 75 years or older (people of Aboriginal or Torres Strait islander background >35 years).

- Residents of aged care or disability care facilities.
- People with:
  - a disability who have impaired cardiac or respiratory function.
  - severe chronic lung disease, asthma, COPD, pulmonary fibrosis or bronchiectasis
  - a significant impairment from a chronic neurological condition
  - congestive heart failure (NYHA class to or greater)
  - obesity (BMI greater than or equal 30)
  - chronic kidney disease (eGFR less than 60 ml/min)
  - diabetes requiring medication for glycaemic control
  - liver cirrhosis
- People who are moderately or severely immunocompromised.
- Pregnant women; particularly those in the second and third trimester, who are at risk from influenza.

Children with the following conditions may be susceptible:

- Severe chronic or complex illness
- Significant cardiac or respiratory problems
- Immunosuppression
- Other risk factors for severe influenza as per: *List. Specified medical conditions associated with increased risk of influenza disease and severe outcomes.*

Further advice on risk factors, supportive care and antiviral therapy for children with COVID is available from the [National COVID-19 Clinical Evidence Taskforce](#).

## Testing

Managing ARI depends on clinical recognition of the syndrome, **not** laboratory diagnosis of a specific virus.

Patients who are managed via an ARI diversion clinic should be tested based on clinical assessment, rather than surveillance.

Testing should be undertaken for those who are at high risk of severe illness; who may require admission to hospital; or who would be eligible for a disease modifying treatment.

If there are likely to be delays receiving the test result, treatment should not be delayed.

For a formal diagnosis, the standard NSW ARI PCR (triplex) will test for influenza, RSV and SARS-CoV-2 (including rapid and urgent PCR tests). Rapid antigen tests (RATs) for COVID-19 will only identify SARS-CoV-2.<sup>14</sup>

More detailed testing recommendations are outlined in the current IPAC/CEC guidelines: *Winter strategy: Testing and IPAC for acute respiratory infection*.<sup>14</sup>

Testing recommendations for an ARI diversion clinic are outlined in [Figure 1](#).

## Infection prevention and control

All patients presenting with any ARI symptoms should be wearing a surgical mask as able and age appropriate. Staff should be wearing a surgical mask with the addition of eyewear for care of any patient presenting with an ARI. A P2/N95 respirator is required for COVID-19 and any ARI where an aerosol generating procedure or behaviour is encountered.

Patients with ARI symptoms, or confirmed influenza, COVID-19 or RSV, should be isolated or managed in cohorts with other cases according to IPAC/CEC guidelines: *Winter strategy: Testing and IPAC for acute respiratory infection*.<sup>14</sup>

Information supporting bed allocation and patient flow can be found in the 2018 *NSW Health Influenza Control Guideline*.<sup>13</sup> Specific infection control guidance for COVID-19 is available in the *CEC COVID-19 Infection Prevention and Control Manual*.

## Patient cohort and management strategies

Patients suitable for management in an ARI diversion clinic include adults and children presenting with mild to moderate, stable differentiated and undifferentiated ARI.

Tables 1 and 2 outline ARI severity definitions and suggested management approaches. The severe and critical presentation definitions have been included in the tables to assist local services to identify which patient presentations are not suitable for management via ARI diversion clinics.

People presenting with severe or critical ARI who are not suitable for diversion and management should follow usual ED escalation and admission protocols.

**Table 1. Severity definitions of ARI in adults (>16 years), with suggested management approach**

Presentation of illness	Definition	Management approach
<b>Mild ARI</b>	<p>An individual with no or mild clinical features, suggestive of mild illness (with consideration for 'between the flags' criteria):</p> <ul style="list-style-type: none"> <li>No OR mild symptoms and signs (fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhoea, loss of taste and smell).</li> <li>No new shortness of breath or difficulty breathing on exertion.</li> <li>No evidence of lower respiratory tract disease during clinical assessment, or on imaging (if performed).</li> <li>Pulse &lt;100bpm, SpO2 &gt;94% on room air.</li> </ul>	<ul style="list-style-type: none"> <li><b>Suitable</b> for review in ARI diversion clinic.</li> <li>Home with advice. In susceptible or high-risk groups, consider the use of an antiviral regime for influenza or COVID-19. Notify general practitioner.</li> <li>For those with COVID-19, assessment and management can be supported by: <a href="#">Emergency department assessment and management of COVID-19 in adults</a>.<sup>15</sup></li> </ul>
<b>Moderate ARI</b>	<p>A stable patient with evidence of lower respiratory tract disease (with consideration for 'between the flags' criteria):</p> <ul style="list-style-type: none"> <li>During clinical assessment, such as <ul style="list-style-type: none"> <li>oxygen saturation 92–94% on room air at rest</li> <li>desaturation or breathlessness with mild exertion.</li> </ul> </li> <li>May have evidence of pneumonia on chest x-ray.</li> </ul>	<ul style="list-style-type: none"> <li><b>May be suitable</b> for review in ARI diversion clinic.</li> <li>Consider admission to hospital for high-risk people. Refer to ED for further assessment or direct admission from clinic if possible.</li> <li>Those unwell enough and requiring hospitalisation with confirmed influenza, consider the use of oseltamavir.</li> <li>For those with COVID-19, refer to <a href="#">Care of adult patients with COVID-19 in acute inpatient wards – a model of care for NSW Health clinicians</a>.<sup>16</sup></li> </ul>

Presentation of illness	Definition	Management approach
<b>Severe ARI</b>	<p>A patient with signs of moderate disease who is deteriorating.</p> <p>OR</p> <p>A patient meeting any of the following criteria (with consideration for 'between the flags' criteria):</p> <ul style="list-style-type: none"> <li>• Respiratory rate <math>\geq</math> 30 breaths/min</li> <li>• Oxygen saturation <math>&lt;</math> 92% on room air at rest or requiring oxygen</li> <li>• Lung infiltrates <math>&gt;</math> 50%</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Not suitable</b> for review in ARI diversion clinic.</li> <li>• Follow usual ED escalation protocols for admission.</li> <li>• Admission to respiratory ward or ICU for management. For COVID-19, refer to <a href="#">Care of adult patients with COVID-19 in acute inpatient wards – a model of care for NSW Health clinicians</a>.<sup>16</sup></li> </ul>
<b>Critical ARI</b>	<p>A patient meeting any of the following criteria (with consideration for 'between the flags' criteria):</p> <ul style="list-style-type: none"> <li>• Respiratory failure, defined as any of the following: <ul style="list-style-type: none"> <li>- Severe respiratory failure (PaO<sub>2</sub>/FiO<sub>2</sub> <math>&lt;</math> 200)</li> <li>- Respiratory distress or acute respiratory distress syndrome (ARDS)</li> <li>- Deteriorating, despite non-invasive forms of respiratory support (i.e. non-invasive ventilation [NIV], or high-flow nasal oxygen [HFNO])</li> <li>- Requiring mechanical ventilation</li> <li>- Hypotension or shock</li> <li>- Impairment of consciousness</li> </ul> </li> <li>• Other organ failure</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Not suitable</b> for review in ARI diversion clinic.</li> <li>• Follow usual ED escalation protocols for admission.</li> <li>• Admission to ICU.</li> </ul>



**Table 2. Severity definitions of ARI in children (<16 years), with suggested management approach**

Presentation of illness	Definition	Management approach
<b>Mild ARI</b>	An individual with clinical features suggestive of mild illness (with consideration for age-appropriate 'between the flags' criteria): <ul style="list-style-type: none"> <li>• Runny nose, cough, sore throat, fever, chills</li> <li>• Breathing normally</li> <li>• Fluid intake and urine output mildly reduced</li> <li>• Feeling unwell</li> <li>• Mild headache; body ache</li> <li>• Less active; fatigue</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Suitable</b> for review in ARI clinic.</li> <li>• Home with advice.</li> <li>• Notify general practitioner.</li> <li>• Consider the use of an antiviral agent for high-risk children with influenza.</li> <li>• For high-risk children with COVID-19, consult with child's usual paediatric care or specialty team and/or paediatric ID.</li> </ul>
<b>Moderate ARI</b>	An individual with clinical features suggestive of moderate illness (with consideration for age-appropriate 'between the flags' criteria): <ul style="list-style-type: none"> <li>• Fever over 39 degrees for days</li> <li>• Mild difficulty breathing when active</li> <li>• Fluid intake half normal; passing urine more than 3 times per day</li> <li>• Concern they are getting more unwell</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Suitable</b> for review in ARI clinic.</li> <li>• Home with advice.</li> <li>• Notify general practitioner. Offer local home-support (such as telephone advice lines; virtual care).</li> <li>• Consider the use of an antiviral agent for high-risk children with influenza.</li> <li>• For high-risk children with COVID-19, consult with paediatric ID.</li> </ul>
<b>Severe ARI</b>	An individual with clinical features suggestive of severe illness (with consideration for age-appropriate 'between the flags' criteria): <ul style="list-style-type: none"> <li>• Baby under 1 month with fever over 38 degrees</li> <li>• Moderate or severe difficulty breathing</li> <li>• Fluid intake less than half normal; passing urine less than 4 times per day</li> <li>• Any other severe symptom, including severe pain, drowsiness, confusion, unable to stand</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Not suitable</b> for review in ARI clinic.</li> <li>• Follow usual ED escalation protocols for admission.</li> <li>• Consider the use of an antiviral agent for all children with influenza if within the first 48 hours. If &gt;48 hours, consult with paediatric ID.</li> <li>• For high-risk children with COVID-19, consult with paediatric ID.</li> </ul>
<b>Critical ARI</b>	An individual meeting the red zone' between the flags' criteria (excluding temperature) and/or the following: <ul style="list-style-type: none"> <li>• Requiring ventilation</li> <li>• Experiencing multiorgan failure or shock</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Not suitable</b> for review in ARI diversion clinic.</li> <li>• Follow usual ED resuscitation and escalation protocols for admission (likely to ICU).</li> </ul>

## Acute treatment for ARI

The anticipated high volume of presentations of ARI means that treatment of diagnosed influenza and COVID-19 must be initiated early.

### Influenza

There are three medications available for the treatment of symptomatic influenza:

- Oseltamivir (Tamiflu)
- Peramivir (Rapivab)
- Zanamivir (Relenza)

These medications have been shown to modestly reduce the time to alleviation of symptoms in people with influenza.<sup>4</sup> These medications should be commenced early in the disease to be most effective; within the **first 48 hours** of symptoms.

For those who are immunocompromised and experience persistent viral replication:

- these treatments may still be of value, even when commenced later (e.g., within four days of symptom onset)
- extending the treatment course to 10 days and/or use of a high dose oseltamivir regime (i.e. 150 mg twice daily) may be considered. This may shorten time to symptom alleviation and viral shedding, but does increase side effects.<sup>17</sup>

Oseltamivir and zanamivir are considered **safe to use in pregnancy and breastfeeding women**.

In terms of prophylaxis, oseltamivir and zanamivir have been shown to prevent influenza infection in susceptible patients with a high level of exposure when given prophylactically within two days of exposure. It should be considered for close contacts of known cases in an outbreak setting within a residential aged care or health facility.

An overview of these medications, including patient population, formulation, dose and administration for influenza treatment and

prophylaxis, is outlined in tables 1 and 2 in [appendix 1](#).

See also [NSW Health policy directive – Statewide Standing Orders for the Supply or Administration of Medication for Public Health Response \(2016\)](#).<sup>18</sup>

### COVID-19

There are six medications available for treatment, pre-exposure and post-exposure prophylaxis for COVID-19:

- Sotrovimab (Xevudy)
- Casirivimab plus imdevimab (Ronapreve)
- Molnupiravir (Lagevrio)
- Nirmatrelvir plus ritonavir (Paxlovid)
- Tixagevimab plus cilgavimab (Evusheld)
- Remdesivir (Veklury)

Generally, these medicines are for use early in the course of the disease, before significant symptoms or severe disease have developed, and within a window of 5 to 7 days from the onset of infection (except for those for use in pre- and post-exposure prophylaxis).

Though the indications for these medications are similar, they are not identical. Eligibility in NSW aligns to either the National COVID-19 Clinical Evidence Taskforce (NCCET) recommendations, Pharmaceutical Benefits Scheme (PBS) criteria or, in the case of tixagevimab plus cilgavimab, the TGA-approved product information criteria.<sup>19</sup>

Individual medicine eligibility criteria should be reviewed with consideration to which COVID-19 variants are likely to be circulating in the community.

Refer to [Guidance for the use of anti-SARS-CoV-2 monoclonal antibodies and antiviral agents as prophylaxis or to prevent severe infection from COVID-19 in NSW](#).

## Principles of operationalising models of care

There are several key principles which should be considered in operationalising this model locally. Delivery may vary between LHDs. This document will evolve based on the experiences of LHDs in the implementation of local delivery models.

### Site selection and layout

The location or layout of an ARI diversion clinic should be in an area of the hospital or health facility which is easily accessible for patients; and where there is reduced risk of patients with an ARI coming into contact with other patients, visitors and healthcare workers.

Where possible, there should be a separate entry and exit to other patient care areas.

The layout should be able to support:

- a waiting area, consultation areas and have suitable ventilation
- access to amenities, such as bathrooms within the location
- a plan to separate vulnerable or high-risk patients from others in the clinic to avoid cross infection.
- a requirement for support services and cleaning
- an allocated location for staff amenities and meal breaks.

### Access and referral

This model is not intended to operate as a walk-in model. It is recommended that there is a screening point prior to patients entering the ED to divert people to the clinic and avoid patients having multiple assessment/triage points.

Access to the clinic should be from:

- ED screening or triage point
- hospital or LHD specialty services
- local primary care practitioners.

Requirements for access should be locally determined, including whether appointments need to be booked and whether a verbal referral is sufficient from any of the above areas.

If at review the patient is found to be too unwell to return home (especially those with respiratory distress or on room air SpO<sub>2</sub> <92%), refer to ED or directly admit to wards, if possible. Ensure receiving staff are aware the patient has an ARI, and they should continue to wear a N95/P2 mask.

A brief letter of attendance, result of testing and action/s taken should be sent back to referrer and GP.

LHDs may also consider access for staff who are referred for management and treatment of ARI.

### Setting and delivery modes

The clinic should support face-to-face and virtual care delivery. Patients may be screened and directed home for a virtual follow-up appointment, if appropriate.

Consideration could be given to a mechanism for virtual screening or clinic appointments. Virtual care services will require access to technology in consultation rooms, as well as a system to book and manage virtual care appointments.

### Staffing

The clinic is intended to be predominantly staffed by nursing workforce. It will require medical oversight, either in person or via virtual care. Specialty and skill mix of clinic staff will be locally determined, but should be comprised of the following:

- Medical or nurse practitioner required to prescribe medications outside existing standing orders.

- Clinical staff with sufficient experience to undertake initial assessment, identify severity and initiate care.
- A role to support triage and screening.
- Medical oversight for referral and escalation of care.
- Critical non-clinical roles, including administrative, cleaning and security staff.

To manage paediatric presentations, the hospital must have paediatric role delineation and suitable staff capability / skill mix.

### Policy and procedures

Procedures should be agreed and implemented for the management of the clinic that suits local needs, including:

- clinical escalation for patients within the clinic, including clinical emergency response and processes for admission to ED or direct admission to wards
- clinical governance, including executive sponsorship
- prescription for antivirals should occur through NSW Health pharmacy to support timely access to treatment
- mechanisms to follow up results and patients, if required
- direct hospital admission from clinic, if required.

Patients attending the ARI clinic should have an outpatient visit created in the electronic medical record or patient administration system, that can be used to record attendance and any clinical documentation as an outpatient. Patients should also be provided with standardised advice on managing their symptoms and treatment, and what to do if their condition deteriorates.

### Equipment

Equipment must be suitable for both adults and children, depending on the local delivery model being operationalised. Minimum clinical requirements include:

- surgical masks for patients
- personal protective equipment for staff
- tympanic thermometers (axillary thermometers for children), pulse oximeters (with adult and paediatric sensor probes), sphygmomanometers (including paediatric-sized blood pressure cuffs)
- examination tables and privacy curtains
- hand hygiene products
- general clinical waste bags/bins; sharps containers
- tissues
- surface cleaning products
- signage and information sheets
- swabs for taking patient specimens and pathology collection process
- resuscitation equipment (adult and paediatric)
- medication standing orders for all appropriate medications
- protocol for clinical emergency response
- oxygen and the means for delivering it to patients.

Minimum communication requirements include:

- telephones
- computers/workstations with access the hospital network, electronic medical record, email and the NSW Health intranet (and/or internet)
- virtual care capable cameras.

ARI diversion clinics should be able to offer COVID-19 RAT and triplex PCR testing.


This list is based on the *Guideline for the Establishment and Operation of COVID-19 Assessment Clinics*.<sup>9</sup>

## Stakeholders and partnerships

Key local partnerships are essential for the successful establishment of a winter surge ARI diversion clinic. Local teams involved by LHDs/SHNs in stepping-up an ARI clinic may include:

- infection prevention and control teams
- pharmacy departments
- community care teams
- general practitioners and general practice teams
- pathology services
- infrastructure and support services
- patient flow
- information technology support (particularly if delivering virtual care options).

**Figure 1. Decision pathway: suitability for management in ARI diversion clinic**



## Appendix 1. Pharmacological treatment for influenza

The medication information outlined in Table 1 (treatment) and Table 2 (prophylaxis) are, as per the [TGA approved Product Information](#) and the [Australian Medicines Handbook](#). This appendix should be viewed in conjunction with these resources. The availability of medications may differ between facilities.

**Table 1. Medications for influenza treatment in adults and children**

	Patient population	Formulation	Dose and administration for TREATMENT	Prophylaxis
Oseltamivir (Tamiflu®)	Suitable in children from birth, adults, pregnant and breastfeeding women	Capsule (30 mg, 45 mg and 75 mg) and oral suspension (6 mg/mL)	<b>Adults:</b> 75 mg twice daily CrCl 30 – 60 mL/min: 30 mg twice daily CrCl 10 – 30 mL/min: 30 mg once daily <b>Child &gt; 1 year:</b> < 15 kg: 30 mg twice daily 15-23 kg: 45 mg twice daily 23-40 kg: 60 mg twice daily > 40 kg: 75 mg twice daily <b>Birth (at term) – 1 year:</b> 3 mg/kg twice daily Treatment course is <b>5 days</b> .	Yes – see <b>Table 2</b>
Zanamavir (Relenza®)	Suitable in children ≥ 5 years, adults, pregnant and breastfeeding women	Powder for insufflation	2 inhalations (= 10 mg) twice daily. No dose adjustment required in renal impairment. Treatment course is <b>5 days</b> .	Yes – see <b>Table 2</b>
Peramavir (Rapivab®)	Suitable in children ≥ 2 years and adults. Avoid in pregnant and breastfeeding women	Intravenous injection	<b>Adults:</b> 600 mg single dose CrCl 30 – 50 mL/min: 200 mg single dose CrCl 10 – 30 mL/min: 100 mg single dose <b>Children 2-13 years:</b> 12 mg/kg single dose	No

**Table 2. Medications for influenza prophylaxis in adults and children**

	Patient population	Formulation	Dose and administration for PROPHYLAXIS
Oseltamivir (Tamiflu®)	Suitable in children from birth, adults, pregnant and breastfeeding women	Capsule (30 mg, 45 mg and 75 mg) and oral suspension (6 mg/mL)	<b>Adults:</b> 75 mg once daily CrCl 30 – 60 mL/min: 30 mg once daily CrCl 10 – 30 mL/min: 30 mg once daily <b>Child &gt; 1 year:</b> < 15 kg: 30 mg once daily 15-23 kg: 45 mg once daily 23-40 kg: 60 mg once daily > 40 kg: 75 mg once daily <b>Birth (at term) – 1 year:</b> 3 mg/kg once daily Treatment course is <b>10 days</b> .

	Patient population	Formulation	Dose and administration for PROPHYLAXIS
Zanamavir (Relenza®)	Suitable in children $\geq$ 5 years, adults, pregnant and breastfeeding women	Powder for insufflation	2 inhalations (= 10 mg) once daily. No dose adjustment required in renal impairment. Treatment course is <b>10 days</b> .

## References

1. NSW Agency for Clinical Innovation. COVID-19 Critical Intelligence Unit: Monoclonal antibodies - in brief [internet]. ACI: Sydney; 2021 [cited 9 June 2022]. Available from: [https://aci.health.nsw.gov.au/\\_\\_data/assets/pdf\\_file/0006/696948/Evidence-Check-Monoclonal-antibodies.pdf](https://aci.health.nsw.gov.au/__data/assets/pdf_file/0006/696948/Evidence-Check-Monoclonal-antibodies.pdf).
2. National COVID-19 Clinical Evidence Taskforce Living Guidelines [internet]. NCCET: Melbourne; 2021 [cited 9 June]. Available from: <https://covid19evidence.net.au/#living-guidelines>.
3. NSW Agency for Clinical Innovation. COVID-19 Critical Intelligence Unit: Rapid access models of care for respiratory illness - in brief [unpublished]. ACI: Sydney; 2022 [cited 9 June 2022].
4. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev. 2014 Apr 10(4):CD008965. DOI: 10.1002/14651858.CD008965.pub4
5. Jefferson T, Jones M, Doshi P, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014 Apr 9;348:g2545. DOI: 10.1136/bmj.g2545
6. Malosh RE, Martin ET, Heikkinen T, et al. Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials. Clin Infect Dis. 2018 May 2;66(10):1492-500. DOI: 10.1093/cid/cix1040
7. Ehrenstein V, Kristensen NR, Monz BU, et al. Oseltamivir in pregnancy and birth outcomes. BMC Infect Dis. 2018 Oct 16;18(1):519. DOI: 10.1186/s12879-018-3423-z
8. NSW Health. Guidelines for the establishment and operation of flu clinics during the PROTECT phase of the response to H1N1 influenza '09 [unpublished]. NSW Health: Sydney; 2009 [cited 9 June 2022].
9. NSW Health. Guideline for the Establishment and Operation of COVID-19 Assessment Clinics [unpublished]. NSW Health: Sydney; 2020 [cited 9 June 2022].
10. Tenforde MW, Morris SB. Multisystem Inflammatory Syndrome in Adults: Coming Into Focus. Chest. 2021 Feb;159(2):471-2. DOI: 10.1016/j.chest.2020.09.097
11. Waseem M, Shariff MA, Tay ET, et al. Multisystem Inflammatory Syndrome in Children. J Emerg Med. 2022 Jan;62(1):28-37. DOI: 10.1016/j.jemermed.2021.07.070
12. NSW Health. NSW Health COVID-19 self isolation guideline [internet]. NSW Health: Sydney; 2022 [cited 9 June 2022]. Available from: <https://www.nsw.gov.au/covid-19/management/self-isolation-covid-and-close>.
13. NSW Health. Influenza control guideline [internet]. NSW Health: Sydney; 2018 [cited 9 June 2022]. Available from: <https://www.health.nsw.gov.au/Infectious/controlguideline/Pages/influenza.aspx#2>.



14. NSW Clinical Excellence Commission. Winter strategy: Testing and IPAC for Acute Respiratory Infection [internet]. CEC: Sydney; 2022 [cited 9 June 2022]. Available from: [https://www.cec.health.nsw.gov.au/\\_\\_data/assets/pdf\\_file/0003/726213/winter-strategy-testing-and-ipac-for-acute-respiratory-infection.pdf](https://www.cec.health.nsw.gov.au/__data/assets/pdf_file/0003/726213/winter-strategy-testing-and-ipac-for-acute-respiratory-infection.pdf).
15. NSW Agency for Clinical Innovation. Emergency department assessment and management of COVID-19 in adults - NSW quick reference guide [internet]. ACI: Sydney; 2022 [cited 9 June 2022]. Available from: <https://www.health.nsw.gov.au/Infectious/covid-19/communities-of-practice/Documents/guide-ed-assessment-management.pdf>.
16. NSW Agency for Clinical Innovation. Care of adult patients with COVID-19 in acute inpatient wards - a model of care for NSW Health clinicians [internet]. ACI: Sydney; 2022 [cited 9 June 2022]. Available from: [https://aci.health.nsw.gov.au/\\_\\_data/assets/pdf\\_file/0003/674526/ACI-Care-of-adult-patients-with-COVID-19-in-acute-inpatient-wards.pdf](https://aci.health.nsw.gov.au/__data/assets/pdf_file/0003/674526/ACI-Care-of-adult-patients-with-COVID-19-in-acute-inpatient-wards.pdf).
17. Mitha E, Krivan G, Jacobs F, et al. Safety, Resistance, and Efficacy Results from a Phase IIIb Study of Conventional- and Double-Dose Oseltamivir Regimens for Treatment of Influenza in Immunocompromised Patients. *Infect Dis Ther*. 2019 Dec;8(4):613-26. DOI: 10.1007/s40121-019-00271-8
18. NSW Health. Statewide Standing Orders for the Supply or Administration of Medication for Public Health Response - policy directive. NSW Health: Sydney; 2022 [cited 10 June 2022]. Available from: [https://www1.health.nsw.gov.au/pds/ActivePDSDocuments/PD2016\\_035.pdf](https://www1.health.nsw.gov.au/pds/ActivePDSDocuments/PD2016_035.pdf).
19. NSW Agency for Clinical Innovation. Guidance for the use of anti-SARS-CoV-2 monoclonal antibodies and antiviral agents as prophylaxis or to prevent severe infection from COVID-19 in NSW [internet]. ACI: Sydney; 2022 [cited 9 June 2022]. Available from: [https://aci.health.nsw.gov.au/\\_\\_data/assets/pdf\\_file/0010/698005/ACI-Guidance-for-use-of-anti-SARS-CoV-2-monoclonal-antibodies-and-antiviral-agents.pdf](https://aci.health.nsw.gov.au/__data/assets/pdf_file/0010/698005/ACI-Guidance-for-use-of-anti-SARS-CoV-2-monoclonal-antibodies-and-antiviral-agents.pdf).

Document information	
<b>Version number</b>	1
<b>Original publication date</b>	14 June 2022
<b>Developed by</b>	Working group comprising representatives of the following specialties: Infectious diseases, respiratory, drugs and therapeutics, emergency medicine, paediatrics, Care in the Community and general practice along with the NSW Agency for Clinical Innovation, Clinical Excellence Commission and Ministry of Health.
<b>Consultation</b>	Collaboration: Clinical working group, Ministry of Health, Clinical Excellence Commission.
<b>Endorsed by</b>	Dr Jean-Frederic Levesque, Chief Executive, NSW Agency for Clinical Innovation
<b>Review date</b>	
<b>Reviewed by</b>	
<b>For use by</b>	Health services and clinicians assessing and managing people with mild to moderate stable acute respiratory infection.